# Who are Yuhan Corporation's customers? Who does Yuhan Corporation earn revenue from?
Canonical: https://valuechain.wiki/yuhan · Facet: customers · Updated: 2026-07-12T04:02:30.988+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Yuhan Corporation's confirmed revenue counterparties include 길리어드 사이언스 (원료의약품 공급), 존슨앤드존슨 (얀센, 렉라자 라이선스아웃) plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 3 revenue edges, backed by 7 dated sources, 4 of them primary filings (as of 2026-07-12).

### 길리어드 사이언스 (원료의약품 공급) (high)  → /gilead-sciences.md
- metric: Amount ₩210.2B · HIV 원료 공급계약
- note: Subsidiary Yuhan Chemical supplies HIV and hepatitis C (HCV) active pharmaceutical ingredients (APIs) to Gilead. HIV API contract KRW 210.2bn (US$139.8m, 9.61% of 2025 consolidated revenue, 2026.05.19); HCV API contract KRW 85.0bn (US$61.3m, 2025.08.26).
- [confirms] FSS DART (KO, filing, published 2026-05-20) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260520800079: "API supply contract. Value KRW 210,191,637,904 (USD 139,810,854), 9.61% of recent revenue KRW 2,186,637,586,358. Counterparty Gilead Sciences. Term 2026-05-19 to 2027-12-31."
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Overseas segment: exports of HIV/AIDS treatment intermediates etc. KRW 386,541m (17.7%); Yuhan Chemical produces APIs (FTC etc.)."
- [confirms] FSS DART (KO, filing, published 2025-08-27) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20250827800028: "HCV treatment API supply contract. Value KRW 84,973,258,500 (USD 61,295,000), 4.11% of revenue. Counterparty Gilead Sciences."

### 브리지바이오 파마 (심근병증 원료의약품 공급) (high)
- metric: Amount ₩56B · 심근병증 원료 공급계약
- note: Supplies cardiomyopathy-drug API to BridgeBio Pharma. Contract KRW 56.0bn (US$38.1m, 2.56% of 2025 consolidated revenue, 2026.05.05 to 2028.03.01).
- [confirms] FSS DART (KO, filing, published 2026-05-06) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260506800401: "Cardiomyopathy-drug API supply contract. Value KRW 55,990,758,000 (USD 38,076,000), 2.56% of revenue. Counterparty BridgeBio Pharma, Inc. Term 2026-05-05 to 2028-03-01."

### 존슨앤드존슨 (얀센, 렉라자 라이선스아웃) (high)  → /johnson-johnson.md
- metric: Amount $950M · 총 기술수출 규모(정정)
- note: Out-licensed Lazertinib to Janssen Biotech in 2018. Current deal size US$950m (revised down from US$1.255bn on 2024.09.20 after the 4th-gen EGFR co-development ended); US$50m upfront plus milestones. J&J's Rybrevant plus Lazcluze combo approved in the US (2024.08), Europe (2025.01), Japan (2025.03) and China (2025.07), driving net-sales royalties. License income was KRW 104.1bn in 2025 (4.8% of revenue).
- [confirms] Edaily (Shinhan Securities) (KO, research, published 2026-05-28) https://edaily.co.kr/News/Read?mediaCodeNo=257&newsId=03066806645446296: "Lazertinib running royalty estimated at 10-15% of J&J's Rybrevant+Lazcluze net sales, received quarterly. Shinhan cut its target to KRW 120,000 from 170,000 on softer-than-expected royalties, keeping Buy."
- [mentions] Asiae (KB Securities) (KO, research, published 2026-05-27) https://www.asiae.co.kr/article/2026052715544105667: "KB Securities initiated coverage with Buy and a KRW 125,000 target, expecting royalty inflows to accelerate."
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Janssen Biotech, Inc. ... total deal US$950,000,000, upfront US$50,000,000, milestones incl. US$60m (2024.09), US$15m (2025.05), US$45m (2025.10), plus running royalty on net sales; a portion of fees is shared with originators Oscotec and Genosco."
- [confirms] Johnson & Johnson Investor News (EN, ir, published 2025-05-31) https://www.investor.jnj.com/investor-news/news-details/2025/RYBREVANT-amivantamab-vmjw-plus-LAZCLUZE-lazertinib-prevents-acquired-resistance-versus-osimertinib-in-first-line-EGFR-mutated-non-small-cell-lung-cancer/default.aspx: "RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated NSCLC."

Reverse side: https://valuechain.wiki/yuhan/suppliers.md · Ripple: https://valuechain.wiki/yuhan/ripple.md

---
Full node: https://valuechain.wiki/yuhan.md · JSON: https://valuechain.wiki/yuhan.json